Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax ...

Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery87% of ...

Investing.com -- MiNK Therapeutics, Inc. (NASDAQ: INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called ...

Shares of MiNK Therapeutics, Inc. (INKT) skyrocketed on Friday following the publication of a case from its clinical trial ...